Oral SERD Therapy in HR+/HER2- Breast Cancer: Testing, Treatment Selection, and Optimizing Patient Care

Meeting Objectives:

• • Discuss the role of biomarker testing in guiding treatment decisions for patients with HR-positive/HER2-negative breast cancer.
  • Evaluate the evolving role of oral SERDs in the treatment of HR-positive/HER2-negative breast cancer, including current and emerging clinical evidence.
  • Identify pharmacist-driven strategies to optimize oral SERD therapy and support patient care.